NASDAQ:AQB

AquaBounty Technologies Competitors

$6.07
-0.12 (-1.94 %)
(As of 04/15/2021 12:36 PM ET)
Add
Compare
Today's Range
$6.07
Now: $6.07
$6.34
50-Day Range
$6.09
MA: $6.88
$7.87
52-Week Range
$1.62
Now: $6.07
$13.32
Volume19,188 shs
Average Volume3.17 million shs
Market Capitalization$430.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27

Competitors

AquaBounty Technologies (NASDAQ:AQB) Vs. GNMK, AMRX, LMNX, CYTK, PRLD, and CSTL

Should you be buying AQB stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to AquaBounty Technologies, including GenMark Diagnostics (GNMK), Amneal Pharmaceuticals (AMRX), Luminex (LMNX), Cytokinetics (CYTK), Prelude Therapeutics (PRLD), and Castle Biosciences (CSTL).

GenMark Diagnostics (NASDAQ:GNMK) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Volatility and Risk

GenMark Diagnostics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares GenMark Diagnostics and AquaBounty Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
AquaBounty Technologies-11,050.81%-36.77%-30.50%

Institutional & Insider Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 60.0% of AquaBounty Technologies shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by company insiders. Comparatively, 42.3% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares GenMark Diagnostics and AquaBounty Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26
AquaBounty Technologies$190,000.002,281.25$-13,230,000.00($0.66)-9.26

AquaBounty Technologies has lower revenue, but higher earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for GenMark Diagnostics and AquaBounty Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
AquaBounty Technologies01102.50

GenMark Diagnostics presently has a consensus target price of $22.0125, indicating a potential downside of 8.24%. AquaBounty Technologies has a consensus target price of $5.8333, indicating a potential downside of 5.91%. Given AquaBounty Technologies' stronger consensus rating and higher probable upside, analysts clearly believe AquaBounty Technologies is more favorable than GenMark Diagnostics.

Summary

AquaBounty Technologies beats GenMark Diagnostics on 9 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Volatility and Risk

Amneal Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares Amneal Pharmaceuticals and AquaBounty Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amneal Pharmaceuticals3.30%42.02%3.82%
AquaBounty Technologies-11,050.81%-36.77%-30.50%

Institutional & Insider Ownership

33.5% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 60.0% of AquaBounty Technologies shares are held by institutional investors. 26.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 42.3% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Amneal Pharmaceuticals and AquaBounty Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$1.63 billion1.09$-361,920,000.00$0.2721.81
AquaBounty Technologies$190,000.002,281.25$-13,230,000.00($0.66)-9.26

AquaBounty Technologies has lower revenue, but higher earnings than Amneal Pharmaceuticals. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Amneal Pharmaceuticals and AquaBounty Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amneal Pharmaceuticals02502.71
AquaBounty Technologies01102.50

Amneal Pharmaceuticals presently has a consensus target price of $6.5714, indicating a potential upside of 11.95%. AquaBounty Technologies has a consensus target price of $5.8333, indicating a potential downside of 5.91%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than AquaBounty Technologies.

Summary

Amneal Pharmaceuticals beats AquaBounty Technologies on 9 of the 13 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Volatility and Risk

Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares Luminex and AquaBounty Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
AquaBounty Technologies-11,050.81%-36.77%-30.50%

Institutional & Insider Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 60.0% of AquaBounty Technologies shares are held by institutional investors. 9.4% of Luminex shares are held by company insiders. Comparatively, 42.3% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Luminex and AquaBounty Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million5.21$-3,840,000.00($0.21)-175.62
AquaBounty Technologies$190,000.002,281.25$-13,230,000.00($0.66)-9.26

Luminex has higher revenue and earnings than AquaBounty Technologies. Luminex is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Luminex and AquaBounty Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex03002.00
AquaBounty Technologies01102.50

Luminex presently has a consensus target price of $37.00, indicating a potential upside of 0.33%. AquaBounty Technologies has a consensus target price of $5.8333, indicating a potential downside of 5.91%. Given Luminex's higher probable upside, analysts clearly believe Luminex is more favorable than AquaBounty Technologies.

Summary

Luminex beats AquaBounty Technologies on 9 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Cytokinetics and AquaBounty Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
AquaBounty Technologies-11,050.81%-36.77%-30.50%

Earnings & Valuation

This table compares Cytokinetics and AquaBounty Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million66.98$-121,690,000.00($2.11)-11.92
AquaBounty Technologies$190,000.002,281.25$-13,230,000.00($0.66)-9.26

AquaBounty Technologies has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Cytokinetics and AquaBounty Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
AquaBounty Technologies01102.50

Cytokinetics presently has a consensus target price of $33.6364, indicating a potential upside of 32.58%. AquaBounty Technologies has a consensus target price of $5.8333, indicating a potential downside of 5.91%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than AquaBounty Technologies.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are held by institutional investors. Comparatively, 60.0% of AquaBounty Technologies shares are held by institutional investors. 6.4% of Cytokinetics shares are held by company insiders. Comparatively, 42.3% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AquaBounty Technologies (NASDAQ:AQB) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares AquaBounty Technologies and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AquaBounty Technologies-11,050.81%-36.77%-30.50%
Prelude TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares AquaBounty Technologies and Prelude Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AquaBounty Technologies$190,000.002,281.25$-13,230,000.00($0.66)-9.26
Prelude TherapeuticsN/AN/AN/AN/AN/A

Prelude Therapeutics has lower revenue, but higher earnings than AquaBounty Technologies.

Analyst Ratings

This is a breakdown of current recommendations and price targets for AquaBounty Technologies and Prelude Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AquaBounty Technologies01102.50
Prelude Therapeutics03102.25

AquaBounty Technologies currently has a consensus target price of $5.8333, indicating a potential downside of 5.91%. Prelude Therapeutics has a consensus target price of $54.25, indicating a potential upside of 51.07%. Given Prelude Therapeutics' higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than AquaBounty Technologies.

Institutional & Insider Ownership

60.0% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. 42.3% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Prelude Therapeutics beats AquaBounty Technologies on 5 of the 8 factors compared between the two stocks.

AquaBounty Technologies (NASDAQ:AQB) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares AquaBounty Technologies and Castle Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AquaBounty Technologies-11,050.81%-36.77%-30.50%
Castle Biosciences-5.30%-2.69%-2.05%

Valuation and Earnings

This table compares AquaBounty Technologies and Castle Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AquaBounty Technologies$190,000.002,281.25$-13,230,000.00($0.66)-9.26
Castle Biosciences$51.87 million33.35$5.28 million($0.81)-85.51

Castle Biosciences has higher revenue and earnings than AquaBounty Technologies. Castle Biosciences is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AquaBounty Technologies has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for AquaBounty Technologies and Castle Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AquaBounty Technologies01102.50
Castle Biosciences00503.00

AquaBounty Technologies currently has a consensus target price of $5.8333, indicating a potential downside of 5.91%. Castle Biosciences has a consensus target price of $83.20, indicating a potential upside of 20.49%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than AquaBounty Technologies.

Institutional & Insider Ownership

60.0% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 66.4% of Castle Biosciences shares are owned by institutional investors. 42.3% of AquaBounty Technologies shares are owned by insiders. Comparatively, 39.7% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Castle Biosciences beats AquaBounty Technologies on 9 of the 14 factors compared between the two stocks.


AquaBounty Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-1.2%$1.74 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.88-0.0%$1.74 billion$334.64 million94.57Analyst Upgrade
Unusual Options Activity
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.16-3.6%$1.74 billion$26.87 million-13.17Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.67-3.9%$1.73 billionN/A0.00Analyst Upgrade
News Coverage
Castle Biosciences logo
CSTL
Castle Biosciences
1.7$69.26-1.0%$1.71 billion$51.87 million-407.39News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.81-1.7%$1.71 billion$428.41 million15.67
Immunocore logo
IMCR
Immunocore
1.3$38.50-2.6%$1.70 billionN/A0.00Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.88-0.0%$1.69 billion$392.76 million13.23Analyst Upgrade
Analyst Revision
News Coverage
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.57-3.3%$1.68 billion$2.34 million-9.99
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.77-1.1%$1.67 billion$102.43 million-19.62
Addus HomeCare logo
ADUS
Addus HomeCare
1.5$108.28-3.1%$1.66 billion$648.79 million0.00
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.53-3.6%$1.66 billionN/A-52.38Gap Down
Establishment Labs logo
ESTA
Establishment Labs
1.2$73.83-4.5%$1.66 billion$89.57 million-43.69Decrease in Short Interest
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.78-1.0%$1.65 billionN/A0.00Analyst Revision
Gap Up
Alphatec logo
ATEC
Alphatec
0.8$17.16-0.3%$1.64 billion$113.43 million-15.60Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.49-5.7%$1.63 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.57-0.2%$1.60 billion$320,000.00-8.55News Coverage
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.76-1.2%$1.59 billionN/A-6.32Increase in Short Interest
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.90-1.0%$1.58 billion$207.89 million-0.32Analyst Downgrade
Codexis logo
CDXS
Codexis
1.1$24.56-0.1%$1.58 billion$68.46 million-70.17Analyst Report
Analyst Revision
News Coverage
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.45-1.0%$1.58 billion$145.97 million-7.06
uniQure logo
QURE
uniQure
1.7$35.64-2.1%$1.57 billion$7.28 million-9.45
Immunovant logo
IMVT
Immunovant
1.8$16.19-1.7%$1.56 billionN/A-12.55Increase in Short Interest
Gap Down
Pulmonx logo
LUNG
Pulmonx
1.4$43.82-0.4%$1.56 billion$32.60 million0.00Increase in Short Interest
BioAtla logo
BCAB
BioAtla
1.7$46.93-1.9%$1.55 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.70-0.6%$1.54 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$26.04-2.4%$1.54 billion$175.34 million-15.32Analyst Report
Analyst Revision
News Coverage
AlloVir logo
ALVR
AlloVir
1.4$23.78-0.9%$1.53 billionN/A0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$38.12-0.5%$1.52 billion$236.54 million-57.76
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.71-1.2%$1.52 billion$82.27 million-18.80
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.97-1.8%$1.50 billion$35.23 million-14.50Increase in Short Interest
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$27.45-3.2%$1.50 billionN/A0.00Insider Selling
Increase in Short Interest
News Coverage
Gap Down
Precigen logo
PGEN
Precigen
1.7$7.43-2.2%$1.50 billion$90.72 million-3.95
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.88-2.3%$1.49 billion$75.86 million-0.34Analyst Upgrade
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.76-2.2%$1.48 billionN/A0.00Insider Selling
Increase in Short Interest
Gap Up
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.94-2.4%$1.48 billionN/A0.00
Apollo Medical logo
AMEH
Apollo Medical
0.8$26.96-0.4%$1.48 billion$560.62 million28.99
Endo International logo
ENDP
Endo International
1.3$6.18-1.5%$1.45 billion$2.91 billion-9.09
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.24-6.0%$1.44 billion$4.23 million-19.44Increase in Short Interest
OLMA
Olema Pharmaceuticals
1.6$35.00-2.5%$1.44 billionN/A0.00Increase in Short Interest
Lantheus logo
LNTH
Lantheus
1.7$21.33-0.1%$1.43 billion$347.34 million266.66Insider Selling
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$31.96-3.8%$1.43 billionN/A0.00Increase in Short Interest
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$63.24-2.8%$1.43 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.56-0.3%$1.42 billionN/A-148.17
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.37-0.5%$1.42 billion$19.89 million-13.38Analyst Report
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$30.65-0.5%$1.42 billionN/A-17.32
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$28.22-0.5%$1.41 billionN/A-3.06Gap Down
Translate Bio logo
TBIO
Translate Bio
1.6$19.40-3.8%$1.40 billion$7.80 million-18.13
ATBPD
Antibe Therapeutics
0.1$3.62-1.1%$1.40 billion$7.51 million-6.03
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.